GLP-1 Receptor Agonists (GLP-1RAs) for treatment of tobacco and alcohol dependence: a systematic review and meta-analysis of randomised controlled trials
- 1University of Bristol
Abstract
BackgroundGlucagon-like peptide-1 receptor agonists (GLP-1RAs) might reduce tobacco and alcohol use. We synthesised evidence from randomised controlled trials (RCTs) on smoking and alcohol outcomes, including secondary outcomes reported in trials conducted for other clinical purposes.
MethodsWe searched MEDLINE, Embase, PsycINFO, Web of Science, CENTRAL, PubMed, and registries for RCTs comparing GLP-1RAs with placebo from inception to August 18, 2026. Smoking and alcohol outcomes were synthesised using random-effects meta-analyses. We assessed risk of bias (RoB) with RoB-2, and certainty of evidence with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
FindingsFourteen trials involving 1149 participants were included; 13 contributed to meta-analyses. Across the 14 trials, 8 recruited participants not seeking either tobacco or alcohol treatment. The other 6 recruited treatment-seeking participants: 3 for tobacco and 3 for alcohol. Eight trials reported smoking-related outcomes, 11 reported alcohol outcomes, and 5 reported both. Follow-up ranged from 6 to 60 weeks.
All 4 pooled smoking-related estimates favoured GLP-1RAs, although all 95% CIs included no difference and were compatible with increases and decreases in outcomes; e.g., smoking cessation, OR 1.39 (95% CI, 0.77 to 2.53, k=3). Restricting analyses to semaglutide trials indicated a reduction in cigarettes per day (CPD) (SMD=-0.10, 95%CI:-0.16 to -0.04; k=3).
Across agents, pooled estimates favoured GLP-1RAs for days without alcohol (SMD=0.35, 95%CI: 0.12 to 0.59, k=3). Pooled estimates of semaglutide-only trials also favoured treatment for alcohol consumption (grams/day; SMD=-0.56, 95%CI:-0.82 to -0.30; k=2), craving (SMD=-0.60, 95%CI:-0.91 to -0.29; k=2), drinks per drinking day (SMD=-0.59, 95%CI:- 0.86 to -0.32; k=3), drinks per calendar day (SMD=-0.48, 95%CI:-0.87 to -0.09; k=2) and heavy drinking days (SMD=-0.45, 95%CI:-0.85 to -0.06; k=3), and alcohol-free days (SMD=0.41, 95%CI:0.09 to 0.73; k=2).
Two of 41 assessed results were at low RoB, 31 raised some concerns and 8 were at high risk; certainty was moderate for 1 outcome, low for 4 and very low for 8.
InterpretationGLP-1RAs may reduce alcohol consumption and CPD, with the clearest evidence for semaglutide. These findings should be contextualised by most evidence being low- to very- low-certainty. Larger trials are needed to establish clinically meaningful benefit and sustained abstinence.
Related
- Evaluation of digital binocular therapies for amblyopia after refractive adaptation in treatment-naive children aged 3–13 years: A systematic review and meta-analysis of randomised controlled trials
- Dietary Enhancement for Iron Deficiency and Anaemia Treatment (DEFeAT): study protocol for a randomised controlled trial to assess the effect of a mineral-enriched powder on iron deficiency in women of reproductive age
- Efficacy of ferrous fumarate with elemental iron 60 mg alternate-day, 120 mg alternate-day vs 60 mg once a day therapy in the treatment of iron deficiency anaemia: study protocol for a randomised controlled trial
- Virtual Reality for Pain, Anxiety, and Patient Experience in Awake Urological Procedures: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
- The Role of Intraoperative Indocyanine Green Fluorescence Angiography in Reducing Anastomotic Leak After Colorectal Resection: A Systematic Review of Randomised Controlled Trials
BibTeX
@misc{taylor2026glp1,
title = {{GLP-1 Receptor Agonists (GLP-1RAs) for treatment of tobacco and alcohol dependence: a systematic review and meta-analysis of randomised controlled trials}},
author = {G. Taylor and C. Burke and D. Titheradge and S. Jia and B. Cihan and I. Faulkner and G. Williams and K. Abeysekera and M. Hickman and K. Thomas},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.21.26366084},
url = {https://www.medrxiv.org/content/10.64898/2026.10.21.26366084v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - GLP-1 Receptor Agonists (GLP-1RAs) for treatment of tobacco and alcohol dependence: a systematic review and meta-analysis of randomised controlled trials
AU - G. Taylor
AU - C. Burke
AU - D. Titheradge
AU - S. Jia
AU - B. Cihan
AU - I. Faulkner
AU - G. Williams
AU - K. Abeysekera
AU - M. Hickman
AU - K. Thomas
PY - 2026
DA - 2026/10/21
PB - medRxiv
DO - 10.64898/2026.10.21.26366084
UR - https://www.medrxiv.org/content/10.64898/2026.10.21.26366084v1
AB - BackgroundGlucagon-like peptide-1 receptor agonists (GLP-1RAs) might reduce tobacco and alcohol use. We synthesised evidence from randomised controlled trials (RCTs) on smoking and alcohol outcomes, including secondary outcomes reported in trials conducted for other clinical purposes. MethodsWe searched MEDLINE, Embase, PsycINFO, Web of Science, CENTRAL, PubMed, and registries for RCTs comparing GLP-1RAs with placebo from inception to August 18, 2026. Smoking and alcohol outcomes were synthesised using random-effects meta-analyses. We assessed risk of bias (RoB) with RoB-2, and certainty of evidence with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. FindingsFourteen trials involving 1149 participants were included; 13 contributed to meta-analyses. Across the 14 trials, 8 recruited participants not seeking either tobacco or alcohol treatment. The other 6 recruited treatment-seeking participants: 3 for tobacco and 3 for alcohol. Eight trials reported smoking-related outcomes, 11 reported alcohol outcomes, and 5 reported both. Follow-up ranged from 6 to 60 weeks. All 4 pooled smoking-related estimates favoured GLP-1RAs, although all 95% CIs included no difference and were compatible with increases and decreases in outcomes; e.g., smoking cessation, OR 1.39 (95% CI, 0.77 to 2.53, k=3). Restricting analyses to semaglutide trials indicated a reduction in cigarettes per day (CPD) (SMD=-0.10, 95%CI:-0.16 to -0.04; k=3). Across agents, pooled estimates favoured GLP-1RAs for days without alcohol (SMD=0.35, 95%CI: 0.12 to 0.59, k=3). Pooled estimates of semaglutide-only trials also favoured treatment for alcohol consumption (grams/day; SMD=-0.56, 95%CI:-0.82 to -0.30; k=2), craving (SMD=-0.60, 95%CI:-0.91 to -0.29; k=2), drinks per drinking day (SMD=-0.59, 95%CI:- 0.86 to -0.32; k=3), drinks per calendar day (SMD=-0.48, 95%CI:-0.87 to -0.09; k=2) and heavy drinking days (SMD=-0.45, 95%CI:-0.85 to -0.06; k=3), and alcohol-free days (SMD=0.41, 95%CI:0.09 to 0.73; k=2). Two of 41 assessed results were at low RoB, 31 raised some concerns and 8 were at high risk; certainty was moderate for 1 outcome, low for 4 and very low for 8. InterpretationGLP-1RAs may reduce alcohol consumption and CPD, with the clearest evidence for semaglutide. These findings should be contextualised by most evidence being low- to very- low-certainty. Larger trials are needed to establish clinically meaningful benefit and sustained abstinence.
ER -